Viscosity
Also known as: Serum Viscosity
Use
Evaluate hyperviscosity syndrome associated with monoclonal gammopathy states (myeloma, macroglobulinemia of Waldenström, and other dysproteinemias), including occasional cases of rheumatoid arthritis, SLE, systemic lupus erythematosus, hyperfibrinogenemia
Special Instructions
Not provided.
Limitations
The test was developed and its performance characteristics determined by Labcorp. It has not been cleared or approved by the Food and Drug Administration. Hyperviscosity occurs most frequently with IgM monoclonal gammopathy, followed by IgA myeloma, and importantly, symptoms can arise at varied relative viscosity levels. Misdiagnosis, such as congenital heart disease, can occur when symptoms overlap. It's crucial to be aware that false diagnoses might arise due to the symptomatic overlap with other conditions.
Methodology
Other
Biomarkers
Viscosity, Serum
Analyte
LOINC Codes
- 3128-6 - Visc Ser
- 3128-6 - Visc Ser
Result Turnaround Time
4-6 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
1 mL
Minimum Volume
0.5 mL
Container
Red-top tube or gel-barrier tube
Storage Instructions
Refrigerate.
Causes for Rejection
Hemolysis; fibrin clots; quantity not sufficient for analysis
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 14 days |
| Refrigerated | 14 days |
| Frozen | 14 days |
Other tests from different labs that may be relevant